BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11866443)

  • 21. Combined suicide gene and immunostimulatory gene therapy using AAV-mediated gene transfer to HPV-16 transformed mouse cell: decrease of oncogenicity and induction of protection.
    Janousková O; Síma P; Kunke D
    Int J Oncol; 2003 Mar; 22(3):569-77. PubMed ID: 12579310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Adenovirus-mediated double suicide gene selectively kills breast cancer MCF-7 cells in vitro].
    Kong H; Huang ZH; Li Q; Yang LC; Yu JL; Li Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun; 28(6):907-10. PubMed ID: 18583225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tegument viral protein 22 enhanced cell-killing effect of the herpes simplex virus thymidine kinase/ganciclovir system on ovarian cancer in vivo].
    Kong BH; Wang WX; Liu CS; Ma DX; Qu X
    Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):195-8. PubMed ID: 12885362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained release of low-dose ganciclovir from a silicone formulation prolonged the survival of rats with gliosarcomas under herpes simplex virus thymidine kinase suicide gene therapy.
    Miura F; Moriuchi S; Maeda M; Sano A; Maruno M; Tsanaclis AM; Marino R; Glorioso JC; Yoshimine T
    Gene Ther; 2002 Dec; 9(24):1653-8. PubMed ID: 12457278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma.
    Tsuchiyama T; Kaneko S; Nakamoto Y; Sakai Y; Honda M; Mukaida N; Kobayashi K
    Cancer Gene Ther; 2003 Apr; 10(4):260-9. PubMed ID: 12679798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of bicistronic lentiviral vector-mediated herpes simplex virus thymidine kinase/ganciclovir system on human lens epithelial cells.
    Yang J; Liu TJ; Lu Y
    Curr Eye Res; 2007 Jan; 32(1):33-42. PubMed ID: 17364733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.
    McCart JA; Ward JM; Lee J; Hu Y; Alexander HR; Libutti SK; Moss B; Bartlett DL
    Cancer Res; 2001 Dec; 61(24):8751-7. PubMed ID: 11751395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-efficacy thymidine kinase gene transfer to ovarian cancer cell lines mediated by herpes simplex virus type 1 vector.
    Wang M; Rancourt C; Navarro JG; Krisky D; Marconi P; Oligino T; Alvarez RD; Siegal GP; Glorioso JC; Curiel DT
    Gynecol Oncol; 1998 Nov; 71(2):278-87. PubMed ID: 9826472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Experimental study of dually targeting gene therapy system for pituitary adenomas].
    Ma CY; Lu YC; Shi JX; Ren CC; Zhu JD; Gu JR
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(4):262-6. PubMed ID: 15854489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heat-directed suicide gene therapy mediated by heat shock protein promoter for gastric cancer.
    Isomoto H; Ohtsuru A; Braiden V; Iwamatsu M; Miki F; Kawashita Y; Mizuta Y; Kaneda Y; Kohno S; Yamashita S
    Oncol Rep; 2006 Mar; 15(3):629-35. PubMed ID: 16465423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Adenovirus-mediated double suicide gene therapy for experimental bladder carcinoma].
    Tan WL; Xie Y; Wu YD; Zhu WH; Zheng SB
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 May; 26(5):594-7. PubMed ID: 16762858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IkappaBalpha and HSV thymidine kinase.
    Moriuchi S; Glorioso JC; Maruno M; Izumoto S; Wolfe D; Huang S; Cohen JB; Yoshimine T
    Cancer Gene Ther; 2005 May; 12(5):487-96. PubMed ID: 15692608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eradication of hepatocellular carcinoma xenografts by radiolabelled, lipiodol-inducible gene therapy.
    Kawashita Y; Ohtsuru A; Miki F; Kuroda H; Morishita M; Kaneda Y; Hatsushiba K; Kanematsu T; Yamashita S
    Gene Ther; 2005 Nov; 12(22):1633-9. PubMed ID: 16079887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Delivery of "suicide" thymidine kinase gene of herpes virus in the complex with cationic peptide into human hepatoma cells in vitro].
    Ignatovich IA; Dizhe EB; Akif'ev BN; Burov SV; Boiarchuk EA; Perevozchikov AP
    Tsitologiia; 2002; 44(5):455-62. PubMed ID: 14696255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
    Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
    J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of HIV-1 TAT peptide as an enhancer of HSV-TK/GCV cancer gene therapy.
    Rautsi O; Lehmusvaara S; Ketola A; Määttä AM; Wahlfors J; Pellinen R
    Cancer Gene Ther; 2008 May; 15(5):303-14. PubMed ID: 18309353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
    Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy.
    Hayashi K; Lee JB; Maitani Y; Toyooka N; Nemoto H; Hayashi T
    J Gene Med; 2006 Aug; 8(8):1056-67. PubMed ID: 16779868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
    Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
    Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct.
    Hakkarainen T; Wahlfors T; Meriläinen O; Loimas S; Hemminki A; Wahlfors J
    J Gene Med; 2005 Jul; 7(7):898-907. PubMed ID: 15759279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.